Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 748

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 748
---
 financing activities                                       |     |      |     |                                 |        |   |     |      |        |   |
| Series A Preferred cash dividend                                           |     |    6 |     |                                 |      — |   |     |      |     (2 | ) |
| Net cash provided by financing activities                                  |     |      |     |                                 |      — |   |     |      |     (2 | ) |
| Decrease in cash and cash equivalents                                      |     |      |     |                                 | (1,889 | ) |     |      | (1,319 | ) |
| Cash and cash equivalents – beginning of period                            |     |      |     |                                 |  4,909 |   |     |      |  1,535 |   |
| Cash and cash equivalents – end of period                                  |     |      |     |                                 |  3,020 |   |     |      |    216 |   |
| Supplementary information(note 9)                                          |     |      |     |                                 |        |   |     |      |        |   |

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements. F-34

#### Kintara Therapeutics, Inc.

### Notes to Condensed Consolidated Interim Financial Statements
<div align='center'>(Unaudited)

September 30, 2024

(expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)</div>

1 Nature of operations, corporate history, and going concern and management plans Nature of operations Kintara Therapeutics, Inc., a Nevada corporation (“Kintara” or, the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing one late-stage therapeutic - REM-001for cutaneous metastatic breast cancer (“CMBC”). In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its current and future product candidates. Merger with TuHURA Biosciences, Inc. On April 2, 2024, the Company entered into a definitive Agreement and Plan of Merger with TuHURA Biosciences, Inc., a Delaware corporation (“TuHURA”), and Kayak Merge